Sign in
CLNN Stock Price, Chart, Stats & News
Clene Inc.
Save
59.48M
Market cap
–
Current P/E
–
Forward P/E
CLNN chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 78.50% |
Operating margin | -11541.50% |
Pretax margin | -13086.50% |
Net margin | -13086.50% |
Effective tax rate | – |
ROA | -144.35% |
ROE | 240.83% |
D/E | -1.23x |
Interest coverage ratio | -8.61x |
CLNN valuation
P/E | – |
P/S | 235.50x |
P/B | -2.64x |
P/CF | -2.50x |
P/FCF | -2.53x |
P/OCF | -2.50x |
PEG | -0.06x |
EV multiple | -1.42x |
About
Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship compound, currently under evaluation across a diverse range of clinical studies. This includes a pivotal Phase 2/3 study intended for regulatory submission in individuals battling amyotrophic lateral sclerosis (ALS).
Similar securities
Based on sector and market capitalization
Report issue